Mersana Therapeutics, Inc. (NasdaqGM: MRSN)
Health Care · Biotechnology · US
$—
+0.04% today · — 1Y
Mersana Therapeutics, Inc. (NasdaqGM: MRSN) operates in the Biotechnology industry within the Health Care sector.
trading between 6.63 and 30.39.
Tweenvest scores Mersana Therapeutics, Inc. across four factors: quality 21/100, value 57/100, growth 62/100. Its strongest factor is growth.
MRSN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $33.18M
- P/E
- —
- EPS
- -14.09
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $30.39
- 52-week low
- $6.63
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 102
- Next earnings
- —
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate. Additionally, Mersana maintains strategic research and development collaborations with Merck KGaA and Asana BioSciences, LLC for the creation of ADC product candidates, leveraging its Fleximer technology. Incorporated in 2001, the company initially operated as Nanopharma Corp. before rebranding as Mersana Therapeutics, Inc. in November 2005, and is headquartered in Cambridge, Massachusetts.
- Founded
- 2001
- Listed since
- Jun 28, 2017
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $441.75 | +0.55% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.61 | +0.34% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.00 | -1.43% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.